This is to inform you that pursuant to Regulation 25(3) of the Securities and Exchange Board of India (LODR) Regulations, 2015 read with Schedule IV of the Companies Act, 2013, a separate ....
Awaiting price reaction for this filing.
The company informed the stock exchanges that a separate meeting of Independent Directors for FY 2025-26 was held on 25th March 2026 at 11:00 A.M. at its corporate office in New Delhi. All Independent Directors were present, and the meeting concluded at 12:50 P.M. The directors reviewed the performance of Non-Independent Directors and the Board as a whole, and assessed the quality, quantity, and timeliness of information flow between the management and the Board. The disclosure was made under SEBI LODR Regulation 25(3) and Schedule IV of the Companies Act, 2013.
This is a routine regulatory compliance filing with no material business or financial impact on shareholders. Investors should note the company has rebranded from Advik Laboratories Limited to MPS Pharmaa Limited.